Novo Nordisk was instrumental in writing the language for the Catalyst to Better Diabetes Care Act, advocating for it, and developing support among members of Congress and other key stakeholders for the bill.
The legislation includes three key parts:
Since the passing of this legislation, the Centers for Disease Control and Prevention (CDC) has issued National Diabetes Report Cards.
Novo Nordisk has also become involved with the Institute of Medicine’s (IOM) Roundtable on Population Health Improvement to advance the diabetes medical education component of the Catalyst Act. View this video to learn more about Novo Nordisk’s commitment to the Roundtable.
© 2016 Novo Nordisk All rights reserved. 0415-00026489-1 January 2016